New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
08:22 EDTCGIXCancer Genetics launches genomic test for FL, MCL
Cancer Genetics announced it has received CLIA and New York state approvals for clinical use of its proprietary mature B-cell neoplasm array, or MatBA for Follicular Lymphoma, or MatBA-FL, and Mantle-Cell Lymphoma, or MatBA-MCL. Both tests further extend the portfolio in hematologic cancers being developed by CGI and both were developed and validated via a research collaboration with Memorial Sloan-Kettering Cancer Center. MatBA-FL and MatBA-MCL assist clinicians in the prognosis of Follicular Lymphoma, or FL, and Mantle-Cell Lymphoma, or MCL. MatBA-FL identifies genomic aberrations that are associated with the high frequency of transformation of FL into Diffuse Large B-Cell Lymphoma, or DLBCL, and shorter overall survival, or OS. MatBA-MCL identifies genomic aberrations that are associated with high frequency of either a leukemic involvement and/or shorter OS. Understanding the potential outcome for the patient is critical in making informed choices about treatment selection, clinical trial involvement and patient management.
News For CGIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
07:32 EDTCGIXCancer Genetics to receive $530,000 through NJ Technology Business Tax Program
Cancer Genetics announced that it has received preliminary approval for a $570,000 tax credit from the New Jersey Technology Business Tax Certificate Transfer Program for the year 2014. The company anticipates that it will be able to transfer this credit and receive approximately $530,000 in cash in mid-December.
December 8, 2014
07:37 EDTCGIXCancer Genetics announces launch of sequencing based panel for CLL
Cancer Genetics announced it has been licensed by the Clinical Laboratory Improvement Amendments to perform Focus::CLL, the company's unique next-generation sequencing-based panel for chronic lymphocytic leukemia and small lymphocytic lymphoma. The panel assesses seven genes with clinical relevance for prognosis, disease management, and treatment selection. The targeted NGS panel was designed to offer actionable and immediately relevant information for clinicians. With an analytical sensitivity of 5%, the test is able to detect biomarker mutations and aberrations that are present at very low levels and which may be missed by other, less sensitive methodologies. Improved sensitivity can lead to enhanced diagnostic and prognostic capabilities for this disease and improved patient outcomes.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use